Welcome to our book review site go-pdf.online!

You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.

Sign up

Cancer Immunotherapy
  • Language: en
  • Pages: 684

Cancer Immunotherapy

Cancer is managed by surgery, radiation therapy, and systemic drug therapies. Drug therapies include endocrine manipulation, single- or multi-agent chemotherapy, and monoclonal antibody therapy. Targeted small molecules that specifically capitalize on vulnerabilities that map to signaling pathways indispensible for tumor growth and progression are now also a part of the standard of cancer care. More recently, rapidly accumulating data illustrates a critical role for the immune system in the response to chemotherapy, radiation (the abscopal effect), and novel targeted cancer therapies. Integrating immune-based therapies strategically with established and novel cancer therapeutics should generate a robust antitumor effect that takes advantage of the strengths of their individual modes of action and also leverages potential immunologic synergies.

Cancer Immunotherapy
  • Language: en
  • Pages: 684

Cancer Immunotherapy

Immunological thought is exerting a growing effect in cancer research, correcting a divorce that occurred in the mainstream of the field decades ago as cancer genetics began to emerge as a dominant movement. During the past decade, a new general consensus has emerged among all cancer researchers that inflammation and immune escape play crucial causal roles in the development and progression of malignancy. This consensus is now driving a new synthesis of thought with great implications for cancer treatments of the future. This book introduces new concepts and practices that will dramatically affect oncology by adding new immune modalities to present standards of care in surgery, radiotherapy ...

Cancer Immunotherapy
  • Language: en
  • Pages: 679

Cancer Immunotherapy

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer, and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumor immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational...

Cancer Pharmacology
  • Language: en
  • Pages: 471

Cancer Pharmacology

Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs, Second Edition is a visually engaging reference detailing the essential basic and clinical science of all approved, effective, and life-prolonging drug therapies in oncology. Now with a greater emphasis on clinical context, application, and management in each chapter, this significantly revised edition provides both early-career and seasoned clinicians with a practical, bench-to-bedside approach and patient-oriented guide. The book provides detailed coverage of the major advances in cancer pharmacology at the forefront of our standards of care for solid tumors and hematologic malignancies, in addition to the basic science that i...

Federal Register
  • Language: en
  • Pages: 884

Federal Register

  • Type: Book
  • -
  • Published: 1998-05
  • -
  • Publisher: Unknown

None

Death Was Not an Option!
  • Language: en
  • Pages: 571

Death Was Not an Option!

On December 18, 2009, Marcy Layman woke up to excruciating abdominal pain, and I rushed her to Swedish Emergency in Issaquah, Washington. After an hour of blood tests and ultrasound treatments, I was instructed to take her to a Swedish hospital in downtown Seattle. Three hours of testing later, we were given the news that Marcy had contracted stage IV inoperable pancreatic cancer and had three to six months to live. This journal will take you on a two-year spiritual, medical, nutritional, emotional, and, in some cases, humorous journey while we were finding stronger love and friendship between ourselves and the search for a cure for this insidious disease. Marcys courageous fight against thi...

Progress Report
  • Language: en
  • Pages: 372

Progress Report

  • Type: Book
  • -
  • Published: 1992
  • -
  • Publisher: Unknown

None

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors
  • Language: en
  • Pages: 89

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors

In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these "checkpoint" proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote...

The Drug Development Paradigm in Oncology
  • Language: en
  • Pages: 145

The Drug Development Paradigm in Oncology

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, th...